Corbus Pharmaceuticals (CRBP) Competitors $18.16 -0.01 (-0.06%) (As of 12:30 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CRBP vs. TNXP, CEMI, REPL, CRON, RLAY, EOLS, DNTH, AVXL, IMNM, and NUVBShould you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include Tonix Pharmaceuticals (TNXP), Chembio Diagnostics (CEMI), Replimune Group (REPL), Cronos Group (CRON), Relay Therapeutics (RLAY), Evolus (EOLS), Dianthus Therapeutics (DNTH), Anavex Life Sciences (AVXL), Immunome (IMNM), and Nuvation Bio (NUVB). These companies are all part of the "medical" sector. Corbus Pharmaceuticals vs. Tonix Pharmaceuticals Chembio Diagnostics Replimune Group Cronos Group Relay Therapeutics Evolus Dianthus Therapeutics Anavex Life Sciences Immunome Nuvation Bio Corbus Pharmaceuticals (NASDAQ:CRBP) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, community ranking, institutional ownership, dividends, profitability and earnings. Which has more risk & volatility, CRBP or TNXP? Corbus Pharmaceuticals has a beta of 2.56, suggesting that its stock price is 156% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 2.06, suggesting that its stock price is 106% more volatile than the S&P 500. Which has stronger valuation & earnings, CRBP or TNXP? Corbus Pharmaceuticals has higher earnings, but lower revenue than Tonix Pharmaceuticals. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorbus Pharmaceuticals$880K251.47-$44.60M-$4.69-3.87Tonix Pharmaceuticals$7.77M2.49-$116.66M-$52.740.00 Do institutionals & insiders have more ownership in CRBP or TNXP? 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 4.0% of Corbus Pharmaceuticals shares are held by company insiders. Comparatively, 0.0% of Tonix Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media refer more to CRBP or TNXP? In the previous week, Corbus Pharmaceuticals had 3 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 13 mentions for Corbus Pharmaceuticals and 10 mentions for Tonix Pharmaceuticals. Tonix Pharmaceuticals' average media sentiment score of 0.35 beat Corbus Pharmaceuticals' score of 0.35 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corbus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tonix Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer CRBP or TNXP? Corbus Pharmaceuticals currently has a consensus target price of $65.86, suggesting a potential upside of 262.45%. Tonix Pharmaceuticals has a consensus target price of $53.50, suggesting a potential upside of 37,789.52%. Given Tonix Pharmaceuticals' higher possible upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Corbus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corbus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CRBP or TNXP more profitable? Corbus Pharmaceuticals has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -1,197.86%. Corbus Pharmaceuticals' return on equity of -42.28% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Corbus PharmaceuticalsN/A -42.28% -32.92% Tonix Pharmaceuticals -1,197.86%-158.64%-112.68% Does the MarketBeat Community believe in CRBP or TNXP? Corbus Pharmaceuticals received 108 more outperform votes than Tonix Pharmaceuticals when rated by MarketBeat users. Likewise, 66.87% of users gave Corbus Pharmaceuticals an outperform vote while only 61.93% of users gave Tonix Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCorbus PharmaceuticalsOutperform Votes44866.87% Underperform Votes22233.13% Tonix PharmaceuticalsOutperform Votes34061.93% Underperform Votes20938.07% SummaryCorbus Pharmaceuticals beats Tonix Pharmaceuticals on 14 of the 19 factors compared between the two stocks. Ad Golden CrestIs Your 401(k) Safe? The Real Risk No One Sees ComingEvery day you wait, your savings are at greater risk. The government isn't slowing down, inflation isn't stopping, and the digital dollar is coming. You can protect yourself—but only if you act now. Don't wake up too late. Get your Digital Dollar Protection today and secure your retirement before the window closes.Click Here For Your Free Guide Get Corbus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRBP vs. The Competition Export to ExcelMetricCorbus PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$221.29M$6.77B$5.22B$8.94BDividend YieldN/A8.03%4.98%4.03%P/E Ratio-3.879.10124.8816.69Price / Sales251.47391.951,276.9391.02Price / CashN/A49.2238.8936.42Price / Book1.479.286.395.98Net Income-$44.60M$154.14M$118.47M$225.08M7 Day Performance-1.89%-3.66%-1.94%-0.37%1 Month Performance-2.78%5.77%2.65%4.23%1 Year Performance369.51%38.38%36.44%27.64% Corbus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRBPCorbus Pharmaceuticals4.8293 of 5 stars$18.16-0.1%$65.86+262.6%+475.0%$221.17M$880,000.00-3.8740Short Interest ↓Analyst RevisionTNXPTonix Pharmaceuticals3.0669 of 5 stars$0.15+6.1%N/A-99.1%$20.44M$12.46M0.00103Earnings ReportAnalyst ForecastShort Interest ↑News CoverageCEMIChembio DiagnosticsN/A$0.46flatN/A+0.0%$16.71M$48.34M-0.38337REPLReplimune Group4.2213 of 5 stars$12.25-2.0%N/A+9.0%$836.92MN/A-3.75210Earnings ReportAnalyst ForecastNews CoverageCRONCronos Group2.0507 of 5 stars$2.15+9.1%N/A+8.0%$821.95M$87.24M-14.33356Short Interest ↓Analyst RevisionNews CoverageRLAYRelay Therapeutics3.529 of 5 stars$6.09-1.1%N/A-24.6%$815.39M$10.01M-2.33304Analyst RevisionEOLSEvolus3.892 of 5 stars$12.67-3.4%N/A+50.9%$802.26M$202.09M-13.92170Short Interest ↑Gap DownDNTHDianthus Therapeutics1.4611 of 5 stars$27.14-2.2%N/A+135.7%$797.10M$2.83M-10.8680Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionAVXLAnavex Life Sciences3.7915 of 5 stars$9.24+1.0%N/A+54.6%$783.55MN/A-18.4840IMNMImmunome1.9171 of 5 stars$12.73-4.0%N/A+40.7%$764.44M$14.02M-1.6640Analyst ForecastNews CoverageNUVBNuvation Bio2.3697 of 5 stars$2.95-2.0%N/A+129.6%$735.27M$2.16M-1.3660Analyst Revision Related Companies and Tools Related Companies TNXP Alternatives CEMI Alternatives REPL Alternatives CRON Alternatives RLAY Alternatives EOLS Alternatives DNTH Alternatives AVXL Alternatives IMNM Alternatives NUVB Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRBP) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersIs Your 401(k) Safe? The Real Risk No One Sees ComingEvery day you wait, your savings are at greater risk. The government isn't slowing down, inflation isn't stopp...Golden Crest | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corbus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
